Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to investigate the use of its deep brain stimulation (DBS) system in treatment-resistant depression (TRD), a form of major depressive disorder (MDD). Breakthrough Device Designation .
Abbott (NYSE: ABT) today announced that it has launched an upgraded version of its NeuroSphere™ myPath™ digital health app with enhanced functionality that will help doctors more closely track their patients as they trial Abbott neurostimulation devices to address their chronic pain. This upgrade is part of .
Now available for use with both Apple and Android devices, the app helps people track pain relief during the treatment journey with neurostimulation devicesUpdated app provides doctors with an. | April 25, 2022
Abbott Strengthens Its Connected Care Technologies with Latest NeuroSphere™ myPath™ Digital Health App prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.